Extended Data Fig. 5: BNT162b2-induced S-specific CD4⁺ and CD8⁺ T cells.

CD4⁺ or CD8⁺ T cell effector-enriched fractions of PBMCs obtained from trial participants on day 1 (pre) and day 29 (1-, 10- and 20-μg dose cohorts, n = 9 each; 30-μg dose cohort, n = 10) were stimulated overnight with overlapping peptide pools covering the wild-type SARS-CoV-2 S (S pool 1 and S pool 2) or RBD for assessment by IFNγ ELISpot. Each data point represents the normalized mean spot count from duplicate wells for one study participant, after subtraction of the medium-only control. Spot count data from two participants from the 20-μg dose cohort could not be normalized and are not plotted. a, b, RBD-specific (a) and S-specific (b) CD4⁺ and CD8⁺ T cell responses for each dose cohort. T cell responses against S pool 1 and S pool 2 were combined for each participant. Due to a nonspecific response to S pool 2, data from 9 of 37 participants were excluded (1 µg = 1; 10 µg = 3; 20 µg = 2; 30 µg = 3) and the total combined spot count data is as follows: 1 µg = 8; 10 µg = 6; 20 µg = 5; 30 µg = 10 data sets for CD4⁺ T cell responses and 1 µg = 9; 10 µg = 7; 20 µg = 4; 30 µg = 7 data sets for CD8⁺ T cell responses. Numbers above each dataset represent the number of participants with a positive T cell response over the total number of participants tested. c, ELISpot example of CD4⁺ and CD8⁺ T cell responses for a 30-μg dose cohort participant on day 1 (pre) and day 29 (post). d, Mapping of vaccine-induced responses of participants with evaluable baseline data (n = 34 for CD4⁺ and n = 37 for CD8⁺ T cell responses) to different portions of S on day 29. Data from 3 participants in the CD4⁺ T cell response and 7 from the CD8⁺ T cell response were excluded due to a nonspecific response to S pool 2. e, ELISpot example of CD4⁺ and CD8⁺ T cell responses on day 85.